Multi-Epitopes Coronavirus (SARS-CoV-2) Vaccine

Tech ID: 32054 / UC Case 2020-642-0

Brief Description

The extremely rapid spread of novel coronavirus disease has now led to over 4 million infections, with limited resources and treatments for this disease. UCI scientists have developed 10 novel formulations for a safe and effective SARS-CoV-2 vaccine, aimed to prevent the development of new cases and the re-infection of those that have recovered.

Suggested uses

·For use as a vaccine against SARS-CoV-2 infection and subsequent COVID-19 disease.

Advantages

·Necessary & Profitable: in order to quell the COVID-19 pandemic, the global population needs a vaccine for immunity against the SARS-CoV-2 virus

·Toxic adjuvant-free: these vaccines are constructed without immune-adjuvants that produce serious side effects

·Protective immunity: antigen sequences are targeted by antibodies within asymptomatic COVID-19 patient blood

·Specificity: these vaccines are comprised of many epitopes instead of whole proteins for a more directed immune response

Technology Description

Globally, over 3.8 million people have contracted SARS-CoV-2 coronavirus to date and over 200,000 have died (5/7/20; coronavirus.jhu.edu). Currently, there are no preventative or therapeutic vaccines for this disease; without a reliable vaccine, immunity is nonexistent for noninfected individuals and continued economic and public health costs are expected. A massive need therefore exists across the world for an effective and safe vaccine.

Researchers at the University of California Irvine recently developed ten candidate vaccines to prevent and treat SARS-CoV-2 infection. These vaccines utilize portions of SARS-CoV-2 proteins that are detected by asymptomatic COVID-19 positive patient antibodies; using this approach, instead of antibodies from severely symptomatic patients, promotes a constructive and specific immune defense without harmful overactivation of the immune system. Additionally, these vaccines overcome serious side effect concerns of previous vaccines by excluding toxic immune adjuvants. This invention is comprised of promising vaccines that could alter the narrative of the COVID-19 pandemic over the next few years.

State Of Development

In vivo: Ten candidate vaccines have been tested for safety and immunogenicity, consisting of specific antibody and cytotoxic T-cell production, in humanized (HLA) transgenic mice and rabbits.

Patent Status

Patent Pending

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • BenMohamed, Lbachir

Other Information

Categorized As

Additional Technologies by these Inventors

  • AN INTEGRAL PART OF
  • Institute for Innovation Logo
  • Institute for Innovation Logo

University of California, Irvine Invention Transfer Group
5141 California Avenue, Suite 200, Irvine,CA 92697-7700
Tel: 949.824.2683 | Fax: 949.824.3880
www.ota.uci.edu | ota@uci.edu

© 2020, The Regents of the University of California
Terms of use | Privacy Notice